Begin with the end in mind then work backward to plan for reaching ambitious goals

—Ashawna Hailey, who left $5.5 million to MAPS in her will

Help create a world where psychedelics are integrated into society by including MAPS in your end of life plans.

Please contact MAPS at (831) 429–6362 jade@maps.org

MAPS in the Media

I am Rebel: The Love Drug

June 20, 2016. National Geographic Channel presents I Am Rebel: The Love Drug, a documentary exploring the history of MDMA in therapy, science, and culture. This episode highlights the life and work of Alexander “Sasha” Shulgin, Ph.D., the pioneering chemist who recognized the therapeutic use of MDMA.

Talks at Google by Rick Doblin, Ph.D.

March 7, 2016. Talks at Google in New York City hosts MAPS Founder Rick Doblin, Ph.D., for a presentation about psychedelic research and politics, the Zendo Project’s psychedelic harm reduction services at Burning Man and other events, and how MAPS is working to develop MDMA-assisted psychotherapy into an FDA-approved prescription treatment. “My career goal is to become a psychedelic therapist,” says Doblin, “We’re predicting that may be possible by 2021.”

DEA Approves First Trial Of Medical Marijuana For PTSD by Christine Jun


Patients in Ecstasy Clinical Trial find Drug Beneficial by Don Lattin

March 19, 2016. Don Lattin of The San Francisco Chronicle interviews MDMA-assisted psychotherapy study participants Andy Gold and John Saul to discuss their experiences of overcoming anxiety associated with life-threatening illness after participating in a MAPS-sponsored clinical trial in Marin, Calif. The article outlines the history of MDMA being used as an adjunct to psychotherapy before and after its criminalization in 1985.

MDMA as a Probe and Treatment for Social Behaviors

by Boris D. Heifets, M.D., Ph.D., Robert C. Malenka, M.D., Ph.D.

July 14, 2016. The peer-reviewed scientific journal Cell publishes a new review of current research into the use of MDMA as an adjunct to psychotherapy for a range of neuropsychiatric disorders. The article summarizes current knowledge about MDMA’s mechanism of action, highlighting its ability to catalyze prosocial, empathogenic effects which may help treat symptoms of medical conditions such as major depressive disorder, social anxiety in autistic adults, posttraumatic stress disorder (PTSD), and schizophrenia.
The DEA Just Approved a Way to Smoke Marijuana Legally for the First Time
by Jen Wieczner
April 22, 2016

How LSD Microdosing Became the Hot New Business Trip
by Andrew Leonard
November 20, 2015

Want to Legalize Medical MDMA? Attend a “Psychedelic Dinner”
by Steven Nelson
February 18, 2016

Patients Legally Take Ecstasy While Receiving Therapy in Marin County
by Emily Turner
February 26, 2016

DEA Approves PTSD Marijuana Study
by Patricia Kime
April 21, 2016

Psychedelic Compounds Like MDMA May be Good for More Than Just a High
by Jyllian Kemsley
March 28, 2016

MDMA Used In Clinical Trial To Help People With Autism
by J.E. Reich
November 30, 2015

DEA Greenlights Marijuana Study to Measure Pot’s Effect on PTSD
by Andrew Blake
April 22, 2016

Mind-Altering Drugs Could Cure PTSD
by Matt Giles
December 22, 2015

Making Psychedelics Mainstream: Interview with Rick Doblin
by April Dembosky
November 30, 2015

Rolling in the Deep
by Kelley McMillan
January 4, 2016

There’s a Plan to Get the World’s Biggest Club Drug Approved for Medical Use by 2021
by Lydia Ramsey
October 20, 2015

Veterans Hope MDMA Can Cure Their PTSD
by Christine Jun
November 11, 2015

Psychedelic Therapy is Healing Mental Illness
by Sarah Long
November 6, 2015

**Rare signed Books**

*LSD My Problem Child* by Albert Hofmann, Ph.D.
Signed, Original, Hardcover

These rare collector’s items are signed by author, chemist, and discoverer of LSD, Albert Hofmann, Ph.D., as well as translator Jonathan Ott. Proceeds support MAPS psychedelic research projects. $1,000

[maps.org/store](http://maps.org/store)

orders@maps.org